Company: CMND
Filing Date: 2025-11-17
Form Type: 424B5
Source: 0001213900-25-111233
Chunk: 45

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-17
Form: 424B5
Chunk 45
---
intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

| ● | the                                                                                           
 ability of our pre-clinical and any future clinical trials to demonstrate safety and efficacy 
 of our future product candidates, and other positive results;                                 |

| ● | the                                                                                       
 timing and focus of our future preclinical studies and clinical trials, and the reporting 
 of data from those studies and trials;                                                    |

| ● | the                                                                                       
 size of the market opportunity for our future product candidates, including our estimates 
 of the number of patients who suffer from the diseases we are targeting;                  |

| ● | the                                                              
 success of competing therapies that are or may become available; |

| ● | the                                                                                        
 beneficial characteristics, safety, efficacy and therapeutic effects of our future product 
 candidates, as well as the potential healthcare costs saved through utilizing our future   
 product candidates;                                                                        |

| ● | the                                                                                                 
 ability of our future product candidate to address needs not currently addressed by the psychedelic 
 industry;                                                                                           |

| ● | our                                                                                  
 ability to obtain and maintain regulatory approval of our future product candidates; |

| ● | our                                                                                              
 plans relating to the further development of our future product candidates, including additional 
 disease states or indications we may pursue;                                                     |

| ● | existing                                                                              
 regulations and regulatory developments in the United States and other jurisdictions; |

| ● | our                                                                                           
 plans and ability to obtain or protect intellectual property rights, including extensions     
 of patent terms where available and our ability to avoid infringing the intellectual property 
 rights of others;                                                                             |

| ● | the                                                                   
 ability of our management team to oversee our drug research programs; |

| ● | the                                                                                     
 need to hire additional personnel and our ability to attract and retain such personnel; |

| ● | our                                                                                         
 estimates regarding expenses, future revenue, capital requirements and needs for additional 
 financing;                                                                                  |

| ● | our                          
 dependence on third parties; |

| ● | our                                                                                         
 ability to compete with other companies who offer products that address similar issues that 
 our future product candidates will address;                                                 |

| ● | our                    
 financial performance; |

<div align='center'>7</div>

| ● | the